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OBJECTIVES The goal of this study was to compare T-wave alternans (TWA), signal-averaged electro-
cardiography (SAECG) and programmed ventricular stimulation (EPS) for arrhythmia risk
stratification in patients undergoing electrophysiology study.
BACKGROUND Accurate identification of patients at increased risk for sustained ventricular arrhythmias is
critical to prevent sudden cardiac death. T-wave alternans is a heart rate dependent measure
of repolarization that correlates with arrhythmia vulnerability in animal and human studies.
Signal-averaged electrocardiography and EPS are more established tests used for risk
stratification.
METHODS This was a prospective, multicenter trial of 313 patients in sinus rhythm who were undergoing
electrophysiologic study. T-wave alternans, assessed with bicycle ergometry, and SAECG
were measured before EPS. The primary end point was sudden cardiac death, sustained
ventricular tachycardia, ventricular fibrillation or appropriate implantable defibrillator (ICD)
therapy, and the secondary end point was any of these arrhythmias or all-cause mortality.
RESULTS Kaplan-Meier survival analysis of the primary end point showed that TWA predicted events
with a relative risk of 10.9, EPS had a relative risk of 7.1 and SAECG had a relative risk of
4.5. The relative risks for the secondary end point were 13.9, 4.7 and 3.3, respectively (p ,
0.05). Multivariate analysis of 11 clinical parameters identified only TWA and EPS as
independent predictors of events. In the prespecified subgroup with known or suspected
ventricular arrhythmias, TWA predicted primary end points with a relative risk of 6.1 and
secondary end points with a relative risk of 8.0.
CONCLUSIONS T-wave alternans is a strong independent predictor of spontaneous ventricular arrhythmias or
death. It performed as well as programmed stimulation and better than SAECG in risk
stratifying patients for life-threatening arrhythmias. (J Am Coll Cardiol 2000;36:2247–53)
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Accurate identification of patients at increased risk for
sustained ventricular arrhythmias is critical for the develop-
ment of effective strategies to prevent sudden cardiac death.
Traditionally, left ventricular ejection fraction and measures
of ambient arrhythmia were used to identify high-risk
See page 2254
cohorts and to evaluate the utility of the prophylactic
administration of antiarrhythmic drugs (1). Unfortunately,
this strategy has not proven beneficial in reducing mortality
(2–5). Recently, programmed ventricular stimulation during
electrophysiology (EPS) testing (6,7), but not signal aver-
aged electrocardiography (SAECG) (8), identified a cohort
with left ventricular dysfunction who had improved survival
with implantable cardioverter-defibrillator (ICD) place-
ment. However, programmed stimulation is invasive and
costly. Accordingly, improved noninvasive markers of ar-
rhythmia vulnerability are needed. In this regard, T-wave
alternans (TWA) is a promising new technique (9).
T-wave alternans is a heart rate-dependent measure of
repolarization (10). Previously, TWA induced with atrial
pacing was shown to predict ventricular arrhythmias in
patients undergoing EPS (11). Subsequently, techniques
were developed to allow assessment of alternans noninva-
sively with exercise. There is a high concordance between
exercise-induced and pacing-induced TWA (12). More-
over, TWA measured noninvasively predicts the induction
of ventricular tachyarrhythmias at EPS (13) as well as
appropriate discharges in patients with ICDs (14). How-
ever, the predictive value of TWA measured noninvasively
in patients undergoing arrhythmia evaluation is unknown.
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Accordingly, this study was a prospective evaluation of the
role of TWA in predicting spontaneous ventricular arrhyth-
mias in a large cohort undergoing EPS. In addition, a
comparison of TWA with SAECG and programmed stim-
ulation was performed.
METHODS
Patient population. This was a prospective, multicenter
study of 337 patients undergoing diagnostic electrophysiol-
ogy studies. Patients were considered for inclusion if they
were in normal sinus rhythm and capable of bicycle exercise.
Beta-adrenergic blocking agents were withheld for at least
24 h before the study to reduce the risk of an inadequate
heart rate response with exercise. Twenty-four patients were
excluded from analysis because of protocol violations (for
example, electrophysiology studies or TWA not performed,
TWA testing performed after electrophysiologic testing,
beta-blockers not withheld). Thus, data are presented on
the cohort of 313 patients enrolled in this trial without a
protocol violation. Informed consent was obtained from
each patient, and the study was approved by the institutional
review boards of the participating institutions.
TWA measurement. T-wave alternans testing was con-
ducted before EPS. Careful skin preparation including mild
abrasion and high resolution electrodes (High-Res, Cam-
bridge Heart, Inc., Bedford, Massachusetts) were used to
minimize noise. T-wave alternans was measured during
submaximal bicycle exercise to achieve a heart rate of 105 to
110 beats/min. Electrocardiographic leads were placed at
the standard 12-lead positions and in an orthogonal X,Y,Z
configuration. Measurements were made with the CH2000
system (Cambridge Heart, Inc., Bedford, Massachusetts)
and utilized a spectral method of analysis designed to allow
detection of alternans in the microvolt range of amplitude.
T-wave alternans was prospectively defined as positive
(TWA1) when it was sustained with an onset heart rate
#110 beats per minute with an alternans amplitude $1.9
mV and alternans ratio $3 in the vector magnitude lead, any
orthogonal lead or two consecutive precordial leads. T-wave
alternans was prospectively defined as negative (TWA2) if
the criteria for a positive test were not met and if no
significant alternans was present for a 1 min period while
the heart rate was greater than or equal to 105 beats/min,
and the tracing was not obscured by noise or ectopic beats.
Otherwise, the TWA test was considered indeterminate.
T-wave alternans tests were read and interpreted by two
independent physician readers blinded to the patient’s
clinical data. The concordance rate between readers was
97% for determinate tests.
Signal averaged electrocardiography. Signal averaged
electrocardiography was performed in the supine resting
position before EPS. Time domain analysis was performed
on signals from orthogonal leads using LP-Pac Q software
(Arrhythmia Research Technology, Inc., Austin, Texas).
The duration of signal collection was determined automat-
ically to reduce mean noise levels to ,0.5 mV. The results
were considered indeterminate if the unfiltered QRS dura-
tion was .120 ms with or without bundle branch block or
if a low noise recording could not be achieved. For inter-
pretable studies, the SAECG was considered positive if two
or three of the standard measurements of the filtered signal
were abnormal: the QRS duration .114 ms, the root mean
square voltage of the terminal 40 ms of the QRS ,20 mV
or the duration of the terminal QRS less than 40 mV
.38 ms.
Programmed ventricular stimulation. The EPS was per-
formed in subjects in the supine, mildly sedated, postab-
sorptive state by standard techniques. Programmed ventric-
ular stimulation was performed using a stimulus duration of
2-ms at an amplitude of two to three times the diastolic
threshold. The stimulation protocol consisted of up to two
or three extrastimuli delivered from the right ventricular
apex and outflow tract at two drive cycle lengths. The
number of extrastimuli employed and detailed protocol used
was individualized at each center. However, for patients
with a history of ventricular tachyarrhythmias, three extra-
stimuli were required. The end point of EPS was the
induction of sustained monomorphic ventricular tachycardia
(.30 s in duration or associated with hemodynamic com-
promise requiring earlier intervention) or the completion of
the stimulation protocol. The induction of ventricular fi-
brillation was defined prospectively as an indeterminate
result.
Assessment of spontaneous ventricular arrhythmias.
Clinical follow-up was obtained at regular intervals. The
primary end point was the occurrence of a ventricular
tachyarrhythmic event (VTE), which was defined prospec-
tively as sudden cardiac death (15), sustained ventricular
tachycardia, ventricular fibrillation, appropriate ICD ther-
apy for a ventricular tachyarrhythmia or cardiac arrest. Of
note, 79 patients received ICDs in this cohort, and all such
devices had stored electrograms to aid in the evaluation of
therapy. The secondary end point of this study was a
ventricular tachyarrhythmic event or all-cause mortality. All
potential end point events were classified blindly by an
independent committee with no knowledge of the results of
previous testing.
Statistical analysis. All results are expressed as mean 6
standard deviation. Proportions were compared with the
Fisher exact test, and continuous variables were compared
with the Student t tests. Kaplan-Meier methods were used
to estimate the cumulative percentage of patients surviving
Abbreviations and Acronyms
EPS 5 programmed ventricular stimulation during
electrophysiology study
ICD 5 implantable cardioverter-defibrillator
SAECG 5 signal averaged electrocardiogram
TWA 5 T-wave alternans
VTE 5 ventricular tachyarrhythmic event
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free from end point events over time. For the estimates of
survival free from VTE, follow-up data were censored at the
time of cardiac surgery (other than coronary artery bypass
surgery), myocardial infarction or initiation or discontinua-
tion of Vaughn Williams class I or III antiarrhythmic drugs.
Censoring for changes of antiarrhythmic drug use was
performed in 22 patients (7.6%) at a follow-up of 195 6 126
days. For analysis of survival free from VTE plus death,
there was no censoring of follow-up data. Comparisons
between the survival curves were made using the log-rank
statistic. All follow-up data were censored at 400 days.
Survival probabilities and relative risks for the Kaplan-
Meier analyses were evaluated at 400 days of follow-up.
Stepwise Cox regression methods were used to examine
the association of risk factors with the time to first occur-
rence of end point events during 400 days of follow-up. The
following variables were included in the analysis: TWA,
SAECG, EPS, age, gender, left ventricular ejection frac-
tion, coronary artery disease, nonischemic dilated cardiomy-
opathy, diabetes, history of revascularization and history of
sustained ventricular arrhythmia. Subgroup analysis was
performed on the prospectively defined cohort with known
or suspected ventricular arrhythmias. A p value ,0.05
(two-tailed) was considered statistically significant for all
analyses.
RESULTS
Patient population. There were 313 patients evaluated in
this study. The mean age of this cohort was 56 6 16, and
the mean left ventricular ejection fraction was 44% 6 18%.
In 34% of patients there was a history of congestive heart
failure, including 22% with New York Heart Association
class II symptoms and 12% with class III symptoms. There
was no structural heart disease in 30% of the cohort. At
baseline evaluation 5.8% of patients were receiving class I
antiarrhythmic drugs, and 5.4% were receiving class III
drugs.
The most frequent indication for EPS was syncope or
presyncope (41%). The other indications included cardiac
arrest in 5% of patients, sustained ventricular tachycardia in
14% and nonsustained ventricular tachycardia in 4%. An
additional 31% of patients were being evaluated for the
diagnosis or treatment of supraventricular arrhythmias. Since
the clinical utility of risk stratification will be restricted to those
patients with known or suspected ventricular arrhythmias, this
cohort was identified prospectively for subgroup analysis.
Clinical features of the full study population and of the
ventricular arrhythmia subgroup are shown in Table 1.
Outcomes of TWA, SAECG and EP tests. For this
cohort the results of TWA were positive in 31% of patients,
negative in 45% and indeterminate in the remaining 24%.
Indeterminate results were due primarily to the inability to
achieve the target heart rate or to frequent ectopy. The
SAECG was positive (abnormal) in 19% of patients, neg-
ative in 56% and indeterminate in the remaining 25%.
Indeterminate results were due primarily to a prolonged
QRS duration (.120 ms) or to excess noise. Finally, the
results of programmed ventricular stimulation were positive
for the induction of sustained monomorphic ventricular
tachycardia in 22% of patients, negative in 60% and inde-
terminate in the remaining 18%. Indeterminate results were
due primarily to the induction of ventricular fibrillation or to
protocol violations. Each of the three tests had roughly
equivalent rates of indeterminacy.
Noninvasive test predictors of programmed stimulation.
The SAECG and TWA testing of patients occurred before
EPS. In 129 patients there were determinate TWA,
SAECG and programmed stimulation results. The statisti-
cal performance of the noninvasive tests in this subgroup of
patients are summarized in Table 2. The relative risk of
TWA for predicting EP outcome was 5.7 (p , 0.0001).
The SAECG was a less sensitive but more specific test
than TWA for predicting EP outcome in this population
(Table 2), suggesting that these two noninvasive tests may
be complementary to predict the results of electrophysiology
testing. To assess this possibility, the performance of com-
Table 1. Clinical Features of the Patient Population and the
Ventricular Arrhythmia Subgroup
All Patients
Ventricular
Arrhythmia
Subgroup
n 313 215
Age (yrs) 56 6 16 60 6 14
Gender (% male) 64 75
Coronary artery disease (%) 41 55
Congestive heart failure (%) 34 45
Ejection fraction 0.44 6 0.18 39 6 18
Table 2. Statistical Performance of the Noninvasive Tests to Predict the Results of EPS
Sensitivity Specificity PPV NPV
Relative
Risk p Value
TWA 77.8% 72.5% 42.9% 92.5% 5.7 , 0.0001
SAECG 55.6% 83.3% 46.9% 87.6% 3.8 , 0.0001
TWA1SAECG1 48.1% 96.1% 76.5% 87.5% 6.1 , 0.0001
TWA1SAECG2 29.6% 76.5% 25.0% 80.4% 1.3 0.6170
TWA2SAECG1 7.4% 87.3% 13.3% 78.1% 0.6 0.7360
TWA2SAECG2 14.8% 40.2% 6.2% 64.1% 0.2 , 0.0001
EPS 5 programmed ventricular stimulation during electrophysiology study; NPV 5 negative predictive value; PPV 5 positive
predictive value; SAECG 5 signal averaged electrocardiogram; TWA 5 T-wave alternans.
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binations of TWA and SAECG to predict EPS outcomes
were calculated. In each case a given noninvasive test result
(e.g., TWA1SAECG1) is compared with the three other
possible results (Table 2). Patients in whom both tests were
abnormal (i.e., TWA1SAECG1) had a high likelihood of
having inducible ventricular tachycardia, as reflected by a
higher specificity (96%) and negative predictive value (88%).
However, this group had a lower sensitivity (48%) than
TWA alone. Conversely, TWA2 SAECG2 had a low
sensitivity (15%) and positive predictive value (6%) for
inducible ventricular tachycardia but also had a lower
specificity (40%) than TWA alone. Outcomes with discor-
dant noninvasive results (i.e., TWA1SAECG2 and
TWA2SAECG1) were less predictive of EPS.
Risk stratification of spontaneous arrhythmias.
Follow-up was obtained in 290 patients with a mean
duration of 297 6 103 days. There were 22 VTE, the
primary end point for this study (see Methods section),
including 15 in patients with ICDs. These included five
patients with sudden death and 17 nonfatal arrhythmias.
The Kaplan-Meier curves of event-free survival are shown
in Figure 1. All three tests significantly discriminated
patients for events. The data for TWA are shown in Panel
A. Patients who were TWA1 had an almost 11-fold
increased risk of experiencing an event compared with
patients who were TWA2 (p , 0.002). The probability of
not experiencing a tachyarrhythmic event at 400 days in the
TWA1 group (i.e., event-free probability) was 0.81, while
it was 0.98 in the TWA2 group. The ventricular tachyar-
rhythmia event-free survival curves for SAECG (Panel B)
and EPS (Panel C) also demonstrate an early and persistent
separation between groups. However, the relative risks of
these tests were less than they were for TWA. The results of
EPS had a relative risk of 7.1 (p , 0.001), while the relative
risk for the SAECG was 4.5 (p , 0.002).
There were 27 secondary end points (VTE or all-cause
mortality) including 10 deaths for this study. Again, of the
three tests evaluated, TWA risk-stratified the population
most accurately with a relative risk of 13.9 (p , 0.001). The
EPS had a relative risk of 4.7 (p , 0.001) to discriminate
patients with this end point, while the SAECG had a
relative risk of 3.3 (p , 0.007).
To evaluate the utility of using both noninvasive tests to
predict spontaneous events, survival analysis was performed
for the primary and secondary end points on all 155 patients
with follow-up data and determinate TWA and SAECG
tests. Four groups were compared in this analysis
(TWA1SAECG1, TWA1SAECG2, TWA2SAECG1
and TWA2SAECG2). There were 9 primary end points
(VTE events) in this group and 10 secondary end points
(VTE or death). The 400-day event-free survival rates are
listed in Table 3. The TWA1SAECG1 group had a
markedly lower event-free survival rate than that of any of
the other groups.
Ventricular arrhythmia subgroup analyses. The ventricu-
lar arrhythmia subgroup was constructed by excluding those
patients referred for evaluation of supraventricular arrhyth-
mia. The majority of these patients (60%) were referred for
the evaluation of syncope or presyncope, with an additional
6% referred for nonsustained ventricular tachycardia. Only
27% had a prior history of sustained ventricular arrhythmia.
Other demographic characteristics for the subgroup are
shown in Table 1. The results from the Kaplan-Meier
Figure 1. Risk stratification of ventricular tachyarrhythmic events. Kaplan-
Meier survival curves are shown for each of the three tests evaluated. A:
T-wave alternans; B: Signal averaged electrocardiography; C: Programmed
ventricular stimulation. EPS 5 programmed ventricular stimulation during
electrophysiology study; SAECG 5 signal averaged electrocardiogram;
TWA 5 T-wave alternans.
Table 3. Event-free Survival at 400 Days for Different
Combinations of TWA and SAECG Outcomes
VTE End
Point
VTE or Death
End Point
TWA1SAECG1 67.7% 67.7%
TWA1SAECG2 97.3% 93.6%
TWA2SAECG1 100% 100%
TWA2SAECG2 97.4% 97.5%
SAECG 5 signal averaged electrocardiogram; TWA 5 T-wave alternans; VTE 5
ventricular tachyarrhythmic event.
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analysis are presented in Table 4. The TWA test had the
highest relative risks for both end points: 6.1 (p , 0.029) for
the VTE end point and 8.0 (p , 0.004) for the VTE or
death end point. The Kaplan-Meier curves of TWA for the
ventricular arrhythmia subgroup are shown in Figure 2.
Predictors of clinical events. To assess the independent
predictors of clinical events, multivariate analysis was per-
formed to evaluate the influence of factors on the hazard
ratio (see Methods section). The end point was VTE or
death (there were not enough events to evaluate the VTE
end point alone). Of the clinical factors evaluated, only the
ejection fraction (relative risk 5 3.7, p , 0.004) and a
history of sustained ventricular arrhythmia (relative risk 5
3.8, p , 0.001) were univariate predictors of events. The
only statistically significant independent predictors of events
were TWA (relative risk 12.2) and EPS (relative risk 3.0),
which had a model chi-square of 20.6 (p , 0.0001). A Cox
regression analysis was performed including the noninvasive
predictors only (that is, excluding EPS). This analysis
revealed that TWA (relative risk 10.9, model chi-square
15.5, p , 0.0001) was the only statistically independent
predictor of events.
DISCUSSION
The major findings of this study are that TWA measured
noninvasively predicts the results of programmed ventricular
stimulation as well as of subsequent spontaneous arrhythmic
events. Compared with SAECG, TWA was a more sensi-
tive predictor of the induction of sustained VT during EPS,
as well as a better discriminator of ventricular tachyarrhyth-
mic events or death. Multivariate analysis showed that
TWA was an independent predictor of clinical arrhythmic
events and not simply a marker of left ventricular dysfunc-
tion or inducible sustained ventricular tachycardia, although
the mean left ventricular ejection fraction was lower in
subjects who were TWA1 compared with those who were
TWA2 (35 6 17% vs. 54 6 13%, p , 0.001).
Comparison with previous studies. The initial studies of
microscopic TWA demonstrated that this phenomenon was
a measure of arrhythmia vulnerability in animals (16,17).
This measure is heart rate-dependent (10), so early studies
evaluated TWA with atrial pacing. Studies in humans
demonstrated that TWA is a sensitive predictor of the
induction of VT (18) or of spontaneous ventricular arrhyth-
mias (10). More recently, techniques were developed to
measure TWA noninvasively with exercise, and a high
concordance between exercise and pacing induced alternans
was documented (12). Hohnloser and colleagues (19)
showed that exercise induced TWA was a better predictor
of ICD shocks than multiple other noninvasive tests,
including measures of baroreflex sensitivity, ambient ar-
rhythmias, QT dispersion and SAECG (13). This study is
the largest trial to date of TWA and confirms that this test
is a measure of arrhythmia vulnerability.
This study also confirms that the SAECG can identify
patients with inducible VT and who are at risk for sponta-
Figure 2. The role of TWA for risk stratification in patients with known
or suspected ventricular arrhythmias. Kaplan-Meier survival curves are
shown based on TWA results. A: Ventricular tachyarrhythmic events is the
end point. B: Ventricular tachyarrhythmic events or death is the end point.
TWA 5 T-wave alternans.
Table 4. Event-free Survival at 400 Days Stratified by Test and Clinical Characteristics for the
Subgroup With Known or Suspected Ventricular Arrhythmias
Number of
Events Relative Risk
Log-rank p
Value
Probability
of Survival
(Positive)
Probability
of Survival
(Negative)
VTE End point
TWA 12 6.1 , 0.029 78.8% 96.6%
EP 15 4.6 , 0.009 76.7% 95.0%
SAECG 15 3.4 , 0.01 77.5% 93.4%
VTE or Death
TWA 15 8.0 , 0.004 74.1% 96.8%
EP 19 2.9 , 0.038 75.4% 91.5%
SAECG 17 2.5 , 0.035 78.4% 91.4%
EP 5 programmed ventricular stimulation during electrophysiology; SAECG 5 signal averaged electrocardiogram; TWA 5
T-wave alternans; VTE 5 ventricular tachyarrhythmic event.
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neous ventricular arrhythmias. The role of the SAECG for
arrhythmia risk stratification is well established (20–22).
However, in this study the SAECG did not perform as well
as TWA for predicting the induction of VT or spontaneous
arrhythmias. Moreover, multivariate analysis indicated that
TWA, but not SAECG, was an independent predictor of
subsequent clinical events. Although the SAECG was not
an independent predictor of events, it may enhance the
prognostic value of TWA, as suggested recently by Ikeda
and colleagues (23) in a study of patients after myocardial
infarction. For instance, only 6% of subjects with both tests
negative (that is, TWA2SAECG2, Table 1) had inducible
VT, suggesting that this group may not need to undergo
invasive testing. In contrast, patients with both tests positive
(TWA1SAECG1) had a more than 10-fold increased risk
of a ventricular tachyarrhythmic event at 400 days compared
with the other groups (Table 2), suggesting that this group
should be treated aggressively.
Our experimental design is deserving of comment. Pa-
tients were recruited prospectively who were in sinus
rhythm and who were undergoing electrophysiology study.
This avoided any bias of primarily choosing patients who
had already experienced life-threatening arrhythmias or had
received defibrillators since risk stratification is not impor-
tant in those subjects. In fact, only 19% of patients had a
history of a sustained ventricular tachyarrhythmia in this
trial. However, the inclusion of some very low-risk patients
without structural heart disease may have increased the
predictive value of the tests. To control for this possibility,
subgroup analysis was performed on patients being evalu-
ated for known or suspected ventricular arrhythmias.
T-wave alternans remained a strong predictor of clinical
events in this group (Fig. 2, Table 4).
Study limitations. Our results must be interpreted in the
face of certain methodologic limitations. T-wave alternans
cannot be measured in all patients. Atrial fibrillation pre-
cludes the accurate assessment of TWA, SAECG and other
dynamic repolarization parameters (24). T-wave alternans
could not be measured in some other subjects because they
could not achieve a heart rate of at least 105 beats per
minute with exercise. In addition, the patient population
and indications for EPS were heterogeneous, so it is possible
that these results do not apply to all subgroups. Another
limitation of this study is that a majority of ventricular
tachyarrhythmic events were nonfatal. This study was not
powered to assess the predictors of mortality only. Since all
such events were confirmed to be ventricular tachyarrhyth-
mias by a blinded, independent events committee, it is
assumed that many of these arrhythmias would have been
fatal in the absence of therapeutic interventions such as
ICDs. Finally, beta-blockers were withheld before TWA
testing was performed. This strategy may have led to
inaccuracies in risk assessment although there was no
difference in TWA results between patients on beta-
blockers before evaluation (39% TWA1) and those not on
beta-blockers (42% TWA1, p 5 0.77).
In summary, this study demonstrates that TWA is an
accurate predictor of the results of EPS and a strong
independent predictor of spontaneous ventricular arrhyth-
mias or death. It performed at least as well as EPS and
better than SAECG to risk stratify patients for life-
threatening arrhythmias. These results indicate that TWA
should be a useful adjunct to the clinical evaluation of
patients with known, suspected or at high risk for ventric-
ular tachyarrhythmias, and it should be considered as a
noninvasive method to identify high-risk subjects for future
preventative trials.
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